Literature DB >> 4344095

Adenovirus susceptibility to human interferon during one-step replication.

J G Gallagher, N Khoobyarian.   

Abstract

Susceptibility of adenovirus types 2, 7, and 12 to human interferon was measured in three human diploid cell strains during a single-cycle infection. Although the relative susceptibility of adenovirus to interferon varied in these cell strains, the final yield of each type in each cell strain decreased as the interferon dose increased. On the other hand, wide difference in interferon susceptibility of adenoviruses and vesicular stomatitis virus (VSV) was noted, as interferon doses above 100 units profoundly inhibited VSV but not the adenoviruses.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4344095      PMCID: PMC422461          DOI: 10.1128/iai.5.6.905-908.1972

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Some factors affecting the interferon-induced antiviral state.

Authors:  S Baron; C E Buckler; H B Levy; R M Friedman
Journal:  Proc Soc Exp Biol Med       Date:  1967 Aug-Sep

2.  Stimulating interaction between viruses (stimulons).

Authors:  C Chany; C Brailovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1967-01       Impact factor: 11.205

3.  Studies of adenovirus-SV40 hybrid viruses, VI. Differential effects of interferon on SV40 and adenovirus T antigen formation in cells infected with SV40 virus, adenoviruses, and adenovirus-SV40 hybrid viruses.

Authors:  M N Oxman; W P Rowe; P H Black
Journal:  Proc Natl Acad Sci U S A       Date:  1967-04       Impact factor: 11.205

4.  Relative effects of interferon on virus plaque formation.

Authors:  B P Riley; S T Toy; G E Gifford
Journal:  Proc Soc Exp Biol Med       Date:  1966 Aug-Sep

5.  Counteraction between interferon and enhancer.

Authors:  N Kato; F Ohta; A Okada
Journal:  Virology       Date:  1966-04       Impact factor: 3.616

6.  A substance enhancing virus growth and antagonistic to interferon action.

Authors:  E T Sheaff; R B Stewart
Journal:  Can J Microbiol       Date:  1968-09       Impact factor: 2.419

7.  Infectious mononucleosis: continuous suspension culture of peripheral blood leucocytes.

Authors:  P R Glade; J A Kasel; H L Moses; J Whang-Peng; P F Hoffman; J K Kammermeyer; L N Chessin
Journal:  Nature       Date:  1968-02-10       Impact factor: 49.962

8.  Adenovirus susceptibility to interferon: sensitivity of types 2,7, and 12 to human interferon.

Authors:  J G Gallagher; N Khoobyarian
Journal:  Proc Soc Exp Biol Med       Date:  1969-01

9.  Factors affecting the sensitivity of different viruses to interferon.

Authors:  J V Hallum; H R Thacore; J S Youngner
Journal:  J Virol       Date:  1970-08       Impact factor: 5.103

10.  Relative antiviral resistance induced in homologous and heterologous cells by cross-reacting interferons.

Authors:  W E Stewart; R Z Lockart
Journal:  J Virol       Date:  1970-12       Impact factor: 5.103

View more
  5 in total

1.  Sensitivity of subgroup F adenoviruses to interferon.

Authors:  C T Tiemessen; A H Kidd
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

2.  Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses.

Authors:  Milena Iacobelli-Martinez; Glen R Nemerow
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

3.  Three strains of influenza A virus (H3N2): interferon sensitivity in vitro and interferon production in volunteers.

Authors:  D D Richman; B R Murphy; S Baron; C Uhlendorf
Journal:  J Clin Microbiol       Date:  1976-03       Impact factor: 5.948

4.  Antiviral effects of bovine interferons on bovine respiratory tract viruses.

Authors:  R W Fulton; M M Downing; J M Cummins
Journal:  J Clin Microbiol       Date:  1984-04       Impact factor: 5.948

5.  Intracellular sensing of complement C3 activates cell autonomous immunity.

Authors:  Jerry C H Tam; Susanna R Bidgood; William A McEwan; Leo C James
Journal:  Science       Date:  2014-09-04       Impact factor: 47.728

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.